Abstract:Background: Individuals with severe mental illness experience increased morbidity and mortality compared to the general population. Adverse effects of antipsychotics, including weight gain, may contribute to the development of metabolic syndrome (MetS), which is associated with increased risks of all-cause and cardiovascular disease mortality. We aim to provide a comprehensive overview of clinical, biochemical and genetic factors associated with MetS among patients with schizophrenia spectrum disorders using second-generation antipsychotics (SGA). Methods: A literature search was performed in Pubmed and Embase to identify all cohort studies, cross-sectional studies and clinical trials investigating associations with MetS in patients with schizophrenia spectrum disorders using SGAs. We extracted and enumerated clinical, biochemical and genetic factors reported to be associated with MetS. We defined factors associated with MetS as factors being reported as associated with MetS in two or more studies. Results: 58 studies were included in this review ( n = 12,123). In total, 62 factors were found to be associated with increased risk of MetS. Thirty one out of 58 studies investigated factors that were reported as associated with MetS in two or more studies. With regard to clinical factors, we found gender, higher age, concomitant use of mood stabilizers, higher baseline and current BMI, earlier SGA exposure, higher dose, longer duration of treatment, psychosis and tobacco smoking to be significantly associated with MetS. Furthermore, the biochemical factors hypo-adiponectinemia, elevated levels of C-reactive protein (CRP) and higher white blood cell (WBC) count were identified as factors associated with MetS. Among pharmacogenetic factors, the rs1414334 C-allele of the HTR2C-gene was associated with MetS in patients using SGA. Conclusion: In this systematic review investigating clinical, biochemical and genetic factors associated with MetS in patients using SGAs we found that higher age, higher baseline BMI, higher current BMI and male as well as female gender were positively associated with MetS across all antipsychotics. This study may set the stage for the application of clinical, biochemical and genetic factors to predict the risk of developing MetS in patients using SGAs. Future research is needed to determine which patients using SGAs are at risk to develop MetS in clinical practice.

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

Correlation of Orexin-A and Brain-Derived Neurotrophic Factor Levels in Metabolic Syndrome and Cognitive Impairment in Schizophrenia Treated with Clozapine

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Metabolic Syndrome and Its Associated Factors Among Patients With Schizophrenia Treated With Second-Generation Antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia

Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics.

Clinical, Biochemical and Genetic Variables Associated With Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders Using Second-Generation Antipsychotics: A Systematic Review

Prevalence of metabolic syndrome and its associated factors in first‐treatment drug‐naïve schizophrenia patients: A large‐scale cross‐sectional study

Gender Differences in Prevalence and Associated Factors of Metabolic Syndrome in First-Treatment and Drug-Naïve Schizophrenia Patients.

Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia

Investigation of metabolic syndrome in inpatients of chronic schizophrenia with long-term clozapine treatment

Association Betweenscapandsrebf1gene Polymorphisms and Metabolic Syndrome in Schizophrenia Patients Treated with Atypical Antipsychotics

Fatty acid desaturase 1/2 (FADS1 and FADS2), fatty acid desaturase indices, and their relationships with metabolic syndrome in female adults with first-episode schizophrenia after antipsychotic medications

Influencing factors of different metabolic status in hospitalized patients with schizophrenia

Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.

Prevalence of metabolic syndrome and its related factors in schizophrenic inpatients

Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia

Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia